You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

ACYCLOVIR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Acyclovir patents expire, and what generic alternatives are available?

Acyclovir is a drug marketed by Actavis Elizabeth, Apotex, Aurobindo Pharma Usa, Cadila, Cadila Pharms Ltd, Carlsbad Technology, Chartwell Molecules, Heritage Pharms, Indoco, Ivax Sub Teva Pharms, Lek Pharm, Mylan, Ranbaxy, Roxane, Strides Pharma, Teva, Teva Pharms, Watson Labs, Yiling, Alembic, Amneal, Padagis Israel, Zydus Lifesciences, Abbvie, Amneal Pharms, Anda Repository, Chartwell Rx, Cipla, Cosette, Fougera Pharms Inc, Glenmark Pharms Sa, Macleods Pharms Ltd, Mylan Pharms Inc, Prinston Inc, Taro, Torrent, Xiromed, Actavis Mid Atlantic, Aurobindo Pharma, Hetero Labs Ltd Iii, Hikma, MSN, Novitium Pharma, Rubicon, Vistapharm, Apotex Inc, Carlsbad, Hetero Labs Ltd V, Square Pharms, Sun Pharm Inds Ltd, Zydus Pharms, Eurohlth Intl Sarl, Apothecon, Chartwell Injectable, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hainan Poly, Hospira, Mylan Labs Ltd, and Teva Parenteral. and is included in eighty-eight NDAs.

The generic ingredient in ACYCLOVIR is acyclovir sodium. There are fifty-six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the acyclovir sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Acyclovir

A generic version of ACYCLOVIR was approved as acyclovir sodium by FRESENIUS KABI USA on May 13th, 1998.

  Try a Trial

Drug patent expirations by year for ACYCLOVIR
Drug Prices for ACYCLOVIR

See drug prices for ACYCLOVIR

Drug Sales Revenue Trends for ACYCLOVIR

See drug sales revenues for ACYCLOVIR

Recent Clinical Trials for ACYCLOVIR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Rehab WeridaN/A
University Hospital, ToulousePhase 1
Ho Chi Minh City Hospital of Dermato-VenereologyN/A

See all ACYCLOVIR clinical trials

Medical Subject Heading (MeSH) Categories for ACYCLOVIR

US Patents and Regulatory Information for ACYCLOVIR

ACYCLOVIR is protected by zero US patents and one FDA Regulatory Exclusivity.

FDA Regulatory Exclusivity protecting ACYCLOVIR

COMPETITIVE GENERIC THERAPY
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan ACYCLOVIR acyclovir TABLET;ORAL 074976-001 Apr 13, 1998 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Hainan Poly ACYCLOVIR SODIUM acyclovir sodium INJECTABLE;INJECTION 218111-001 Jan 8, 2024 AP RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Xiromed ACYCLOVIR acyclovir OINTMENT;TOPICAL 201501-001 Jan 29, 2020 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.